CA2296366A1 - Traitement des leucocytes, compositions leucocytaires, et leur procede d'utilisation - Google Patents

Traitement des leucocytes, compositions leucocytaires, et leur procede d'utilisation Download PDF

Info

Publication number
CA2296366A1
CA2296366A1 CA002296366A CA2296366A CA2296366A1 CA 2296366 A1 CA2296366 A1 CA 2296366A1 CA 002296366 A CA002296366 A CA 002296366A CA 2296366 A CA2296366 A CA 2296366A CA 2296366 A1 CA2296366 A1 CA 2296366A1
Authority
CA
Canada
Prior art keywords
cells
leukocytes
cell
leukocyte
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002296366A
Other languages
English (en)
Inventor
William M. Greenman
Joshua A. Grass
Sohel Talib
Adonis Stassinopoulos
Derek J. Hei
John E. Hearst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2296366A1 publication Critical patent/CA2296366A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes et des compositions permettant de traiter des leucocytes de manière à stopper leur prolifération et à les rendre incapables de déclencher des réactions du greffon contre l'hôte, mais capables d'améliorer la greffe de cellules de donneurs allogéniques et d'accélérer la destruction de cellules malades ou d'agents pathogènes. L'invention concerne également des compositions leucocytaires et des méthodes d'utilisation de ces compositions visant à atténuer des maladies, à accélérer plusieurs types de reconstitution du système immunitaire et d'immunothérapies, et à améliorer la greffe de cellules de donneurs allogéniques.
CA002296366A 1997-07-21 1998-07-21 Traitement des leucocytes, compositions leucocytaires, et leur procede d'utilisation Abandoned CA2296366A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5359997P 1997-07-21 1997-07-21
US60/053,599 1997-07-21
US11970798A 1998-07-20 1998-07-20
US09/119,707 1998-07-20
PCT/US1998/015067 WO1999003976A2 (fr) 1997-07-21 1998-07-21 Traitement des leucocytes, compositions leucocytaires, et leur procede d'utilisation

Publications (1)

Publication Number Publication Date
CA2296366A1 true CA2296366A1 (fr) 1999-01-28

Family

ID=26732039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002296366A Abandoned CA2296366A1 (fr) 1997-07-21 1998-07-21 Traitement des leucocytes, compositions leucocytaires, et leur procede d'utilisation

Country Status (6)

Country Link
EP (1) EP1005531A2 (fr)
JP (1) JP2003520563A (fr)
CN (1) CN1270630A (fr)
AU (1) AU748074B2 (fr)
CA (1) CA2296366A1 (fr)
WO (1) WO1999003976A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781855B2 (en) * 1999-10-05 2005-06-16 Hopital Maisonneuve-Rosemont Rhodamine derivatives for photodynamic diagnosis and treatment
US8409564B2 (en) 1999-10-05 2013-04-02 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
AU2002218019A1 (en) * 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
DE102011085695A1 (de) * 2011-11-03 2013-05-08 Jörg Pohl Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten
US20130252227A1 (en) * 2012-03-20 2013-09-26 Fenwal, Inc. Apparatus and Method for Providing Cryopreserved ECP-Treated Mononuclear Cells
US20190224494A1 (en) * 2012-03-20 2019-07-25 Fenwal, Inc. Apparatus and method for batch photoactivation of mononuclear cells with cryopreservation
WO2016073381A1 (fr) * 2014-11-03 2016-05-12 Cerus Corporation Compositions et procédés pour thérapies par cellules car-t améliorées
EP3058957A1 (fr) * 2015-02-19 2016-08-24 Kiadis Pharma Intellectual Property BV Traitement photodynamique amélioré et produit ainsi obtenu
CN104788373A (zh) * 2015-05-06 2015-07-22 武汉大学 化合物s-303盐酸盐的合成方法
EP3313418B1 (fr) 2015-06-26 2024-03-13 Cerus Corporation Compositions de cryoprécipités et leurs procédés de préparation
US10898522B2 (en) 2015-08-19 2021-01-26 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
CA3003097A1 (fr) 2015-10-23 2017-04-27 Cerus Corporation Compositions de plasma et leurs procedes d'utilisation
US20190369087A1 (en) 2016-12-23 2019-12-05 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
CA3055203A1 (fr) 2017-03-03 2018-09-07 Cerus Corporation Kits et methodes de preparation de compositions de plaquettes inactivees par des agents pathogenes
US11679193B2 (en) 2017-12-20 2023-06-20 Fenwal, Inc. System and method of collecting and infusing an apoptotic white blood cell component and a transplant component
AU2018395525B2 (en) 2017-12-29 2023-09-14 Cerus Corporation Systems and methods for treating biological fluids
FR3082730B1 (fr) 2018-06-21 2022-04-22 Med Inn Pharma Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique
CN109337758A (zh) * 2018-11-30 2019-02-15 广西科技大学 一种基于紫外线强化dna与黄曲霉毒素嵌合作用的油脂黄曲霉毒素俘获消除方法
JP7571063B2 (ja) 2019-06-22 2024-10-22 シーラス コーポレイション 生物学的流体の処理を実施するシステム及び方法
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
CN114269394A (zh) 2019-06-28 2022-04-01 塞鲁斯公司 用于实现生物流体处理装置的系统和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation
WO1996039820A1 (fr) * 1995-06-07 1996-12-19 Cerus Corporation Procedes d'inactivation de leucocytes et d'inhibition de la production de cytokines dans des produits sanguins

Also Published As

Publication number Publication date
JP2003520563A (ja) 2003-07-08
CN1270630A (zh) 2000-10-18
WO1999003976A2 (fr) 1999-01-28
WO1999003976A3 (fr) 1999-05-27
EP1005531A2 (fr) 2000-06-07
AU8577698A (en) 1999-02-10
AU748074B2 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AU748074B2 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
JP5707284B2 (ja) 腫瘍の処置のための、インビトロでの部分的に成熟した樹状細胞の投与
KR20200068762A (ko) 면역자극성 항원제시세포를 수득하기 위한 장치 및 방법
KR102917032B1 (ko) 소분자 절제 화합물을 이용한 암 면역 요법에 대한 면역 세포 활성의 생체외 향상 방법
JP2006510667A5 (fr)
KR20130033354A (ko) Ｎｋ세포 강화형 혈액제제의 제조 방법
AU757443B2 (en) New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
KR101900807B1 (ko) 헬퍼 t1 특성들 및 세포용해 특성들을 발현하는 세포들
US20030149011A1 (en) Methods and reagents for extracorporeal immunomodulatory therapy
JP6985939B2 (ja) 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞
JP2004505058A (ja) 悪性腫瘍の免疫治療のための薬剤
JP2002501726A (ja) 抗原提示および免疫応答を高める、改善された体外方法
JPWO2008143014A1 (ja) がん治療剤
WO2009008666A2 (fr) Cellule dendritique autologue médiatisée par une thérapie photodynamique ayant l'aptitude d'inhiber la croissance d'une tumeur
ES2927913B2 (es) Composición que comprende una combinación de las furanocumarinas psoraleno y angelicina y su uso en terapia
WO2023006982A1 (fr) Procédés pour réduire sélectivement l'immunogénicité dans un transplant
HK1030433A (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
Guinan et al. Preservation of immune repertoire by selective depletion of haploidentical grafts
Obochi Prevention of skin allograft rejection by photodynamic therapy (PDT) using benzoporphyrin derivative monoacid ring A (BPD) verteporfin
Dai TH9402 mediated photodynamic therapy: implications for ex vivo purging and tumor vaccination

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued